Investigational drug · Phase 3
CM310
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
3 still active
All registered trials
29
Any phase or sponsor naming "CM310"
First trial start
2023
Apr 28, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CM310", any sponsor or status.
- Phase 218
Conditions studied
As listed on its trial records.
- Atopic Dermatitis
- Moderate to Severe Asthma
- Chronic Obstructive Pulmonary Disease
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Asthma · COPD · Immunology and inflammation · Respiratory · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "CM310" as an intervention, largest first.
- A Study of CM310 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingNot yet recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT06547333 · 884 participants (planned) · Start Sep 13, 2024 · Primary completion Apr 29, 2032
Drug: CM310; Placebo · For: Chronic Obstructive Pulmonary Disease
- A Study of CM310 in Subjects With Moderate to Severe AsthmaPivotal-lookingRecruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT05761028 · 600 participants (planned) · Start Apr 28, 2023 · Primary completion May 2032
Drug: CM310 · For: Moderate to Severe Asthma
Sites: Beijing, China
- A Study of CM310 in Patients With Moderate-to-Severe Atopic DermatitisPivotal-lookingCompleted
Keymed Biosciences Co.LtdIndustry
NCT05265923 · 500 participants · Start Apr 22, 2022 · Primary completion Oct 31, 2023
Drug: CM310 · For: Atopic Dermatitis
Sites: Beijing, China
Keymed Biosciences Co.LtdIndustry
NCT06116565 · 263 participants · Start Dec 21, 2023 · Primary completion Nov 26, 2025
Drug: CM310 · For: Atopic Dermatitis
Sites: Beijing, China
- Study to Evaluate Pharmacokinetics, Safety and Efficacy of CM310Pivotal-lookingCompleted
Keymed Biosciences Co.LtdIndustry
NCT05702450 · 240 participants · Start Mar 22, 2023 · Primary completion Jul 26, 2023
Drug: CM310 · For: Healthy
Sites: Zibo, China
- Study Evaluating the Pharmacokinetics of CM310 in Healthy SubjectsPivotal-lookingStatus unknown
Keymed Biosciences Co.LtdIndustry
NCT06171048 · 236 participants (planned) · Start Apr 30, 2024 · Primary completion Apr 30, 2025
Drug: CM310 · For: Healthy
Sites: Hefei, China
- A Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CROWNS-2)Pivotal-lookingCompleted
Keymed Biosciences Co.LtdIndustry
NCT05436275 · 180 participants · Start Aug 9, 2022 · Primary completion Jun 25, 2024
Drug: CM310; Placebo · For: Chronic Rhinosinusitis With Nasal Polyposis
Sites: Beijing, China
- Study of CM310 Injection in Adolescent Subjects With Atopic DermatisPivotal-lookingCompleted
Keymed Biosciences Co.LtdIndustry
NCT06277765 · 180 participants · Start Mar 21, 2024 · Primary completion Jan 23, 2025
Drug: CM310 · For: Atopic Dermatitis
Sites: Beijing, China
- Study of CM310 in Adolescent Subjects With Atopic DermatisPivotal-lookingActive, not recruiting
Keymed Biosciences Co.LtdIndustry
NCT06495229 · 180 participants (planned) · Start Aug 2, 2024 · Primary completion Aug 30, 2026
Drug: CM310 · For: Atopic Dermatitis
Sites: Beijing, China
- Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic DermatitisPivotal-lookingCompleted
Keymed Biosciences Co.LtdIndustry
NCT05715320 · 160 participants · Start Mar 10, 2023 · Primary completion Jul 18, 2024
Drug: CM310 · For: Atopic Dermatitis
Sites: Hangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Stapokibart (CM310) in Atopic Dermatitis: A Narrative Review of a Next-Generation IL-4Rα Antagonist.
Ferreira E, Wu T, Chen Y · Dermatol Pract Concept 2026
- [A prospective real-world study of stapokibart in the treatment of moderate to severe seasonal allergic rhinitis].
Cheng X, Zhou L, Zhou T, et al. · Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2026
- Evaluating the efficacy and safety of Stapokibart (CM310) in the treatment of uncontrolled seasonal allergic rhinitis based on real-world research.
Chen J, Lu K, Tang P, et al. · Eur Arch Otorhinolaryngol 2026
- Successful Treatment with Stapokibart in a Severe Uncontrolled CRSwNP Patient: A Case of Rapid Symptom Resolution After Biologic and Surgical Failures.
Cai H, Zhou T, Li SZ, et al. · Ear Nose Throat J 2026
- A case report of IgA-mediated anti-Laminin-γ1 (p200) pemphigoid successfully treated with stapokibart combined with corticosteroids.
Zhang T, Liu Y, Zhang Z, et al. · Front Immunol 2026
- Successful use of stapokibart as a biological therapy for allergic fungal rhinosinusitis: a case report.
Cai H, Luo XJ, Cao YQ, et al. · Front Allergy 2025
Also in development for Atopic Dermatitis
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
- ICP-332Phase 34 trials
Beijing InnoCare Pharma Tech Co., Ltd. · Non Segmental Vitiligo, Chronic Spontaneous Urticaria (CSU), Atopic Dermatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.